Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Biosimilars / GBMA Position on Biosimilars / Awareness and Uptake

Awareness and Uptake

Education and awareness of biosimilars for healthcare professionals and consumers is essential

  • GBMA supports the Australian Government’s commitment of $20million over 2015-18 for a biosimilars education and awareness initiative. However, education can only go so far in driving acceptance and uptake of biosimilars.

Uptake drivers must be introduced to support a functioning and competitive biosimilars market in Australia

  • Around the world, the markets best-placed to capitalise on the benefits of biosimilars are those with a functioning competitive market, where multiple manufacturers are motivated to participate over the longer term, and where physicians are at the heart of the decision-making process.
  • Successful biosimilar markets are characterised by the introduction of uptake drivers that encourage physicians to prescribe biosimilars and incentivise patients to accept biosimilars.

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Announcement of Independent Chair

December 9, 2020

9 December 2020 Canberra, ACT Global health policy powerhouse, Jane Halton AO PSM, joins GBMA as its inaugural Independent … More...

Confidence in biosimilar medicines, amongst specialists, GP’s and Pharmacists

December 8, 2020

12 November 2020 Canberra, ACT New research shows prescriber … More...

IGBA Launches First Global Biosimilars Week

December 7, 2020

16 November 2020 Geneva, Switzerland Today the International Generic and … More…

© 2021 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us